News & Events

News


Wednesday April 26, 2017

Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering

SAN DIEGO, April 26, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the pricing of its offering of $450.0 million aggregate principal amount of 2.25% convertible senior notes due 2024 (the "notes"). The notes will be sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The sale of the notes is expected to close on May 2, 2017, subject to customary closing conditions. Neurocrine also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $67.5 million aggregate principal amount of notes. The notes will be senior unsecured ...


Tuesday April 25, 2017

Neurocrine Announces Proposed Convertible Senior Notes Offering

SAN DIEGO, April 25, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Neurocrine also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $67.5 million aggregate principal amount of notes.  The notes will be senior unsecured obligations of Neurocrine and will accrue interest payable semiannually in arrears. Th...


Friday April 21, 2017

Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting

Additional results from largest ever clinical program in tardive dyskinesia to be highlighted as platform and poster presentations SAN DIEGO, April 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that long-term safety and efficacy data from the KINECT 3 Phase III extension study of INGREZZA™ (valbenazine) capsules for the treatment of adults with tardive dyskinesia will be presented as a platform presentation at the American Academy of Neurology (AAN) Annual Meeting April 22-28, 2017 in Boston. Additionally, two posters representing additional data from several clinical trials of INGREZZA will be presented, including an analysis of its pharmacologic ch...


Tuesday April 11, 2017

Neurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)

Provides significant and rapid reduction in involuntary movements with simple once-daily dosing Enables treatment of TD with commonly prescribed psychiatric medication regimens Investor conference call and webcast scheduled for today at 5:30 pm ET (2:30 pm PT) SAN DIEGO, April 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved INGREZZATM (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). INGREZZA, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is the first and only FDA-approved product indicated for the treatment of adults with TD. ...


Tuesday March 21, 2017

Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM (valbenazine) for the Treatment of Tardive Dyskinesia

- Phase III study conducted in patients with tardive dyskinesia shows significant and meaningful reduction in symptoms with INGREZZA - INGREZZA clinical development program is largest ever in tardive dyskinesia with over 1,000 persons having participated in 20 clinical trials SAN DIEGO, March 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurologic, psychiatric and endocrine related disorders, announced today that positive results from the Kinect 3 Phase III study of INGREZZA (valbenazine) for the treatment of tardive dyskinesia (TD) were published online by the American Journal of Psychiatry (DOI: 10.1176/appi.ajp.2017.160910...

Events